Senate Bill No. 394 enacts R.S. 22:1060.8, which mandates that health coverage plans in Louisiana must provide coverage for drugs approved by the United States Food and Drug Administration (FDA) when prescribed for off-label use in minors, under specific conditions. These conditions include that the drug must be prescribed for the treatment of a life-threatening, chronic, or seriously debilitating disease or condition, and it must be recognized for such use by reputable medical sources or peer-reviewed journals. Additionally, the drug must be included on the insurer's formulary or preferred drug list. The bill also outlines the responsibilities of prescribers to provide documentation to insurers and specifies that coverage must include medically necessary services related to the administration of the drug.

The bill clarifies that coverage is not required for treatments excluded under the health coverage plan, experimental drugs not approved by the FDA, or drugs not listed on the insurer's formulary. Furthermore, the coverage may be subject to standard cost-sharing provisions such as deductibles and copayments. The act is set to take effect on January 1, 2023, unless vetoed by the governor and subsequently approved by the legislature.